Welcome to our dedicated page for Halozyme Thrp SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Halozyme Therapeutics, Inc. (HALO) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biopharmaceutical company, Halozyme uses Forms 10-K, 10-Q and 8-K to report on its drug delivery business, collaborations, financing activities and governance matters.
Through current reports on Form 8-K, Halozyme discloses material events such as the issuance of convertible senior notes due 2031 and 2032, amendments to its revolving credit facility, entry into and completion of the Elektrofi acquisition, significant collaboration agreements, and executive appointments or transitions. These filings often include details on note terms, capped call transactions, credit covenants and merger conditions that are not fully described in press releases.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (not reproduced here but referenced in 8-Ks) typically contain broader discussions of Halozyme’s ENHANZE, Hypercon and MDASE technology portfolios, risk factors, royalty and collaboration structures, and overall financial condition. Investors use these filings to understand how platform licensing, proprietary products and acquisitions contribute to the company’s long-term strategy.
Stock Titan enhances this information with AI-powered summaries that highlight key terms in lengthy documents, such as conversion conditions for the company’s notes, leverage and coverage ratios in its credit agreement, and the main obligations and covenants in merger contracts. Users can also review disclosures related to executive compensation arrangements, transition agreements and other governance topics reported under Item 5.02 of Form 8-K.
By combining real-time updates from EDGAR with AI-generated explanations, the Halozyme filings page helps readers quickly locate and interpret the sections of 10-Ks, 10-Qs, 8-Ks and related exhibits that are most relevant to their analysis of HALO stock.
HALOZYME THERAPEUTICS, INC. director Matthew L. Posard received equity awards as part of the company’s director compensation program. He was granted 3,796 restricted stock units, each representing one future share of common stock, and options for 6,040 shares at an exercise price of $65.87 per share.
The RSUs and options vest in full on the earlier of May 5, 2027 or the next annual meeting of stockholders. The RSUs are subject to a deferral election so shares are delivered when he completes his service as a director. After these grants, he directly holds 77,835 common shares.
HALOZYME THERAPEUTICS, INC. director Mahesh Krishnan received equity awards consisting of common stock and stock options as part of the company’s director compensation program. He acquired 3,796 shares of common stock at no cash cost through a restricted stock unit grant.
He was also granted options to purchase 6,040 shares of common stock at an exercise price of $65.87 per share, expiring on May 5, 2036. Both the RSUs and options vest in full on the earlier of May 5, 2027 or the company’s next annual meeting of stockholders. After these grants, he directly holds 14,462 shares of common stock.
Halozyme Therapeutics director James Paul Lang received equity awards as part of the company’s director compensation program. He was granted 3,796 restricted stock units, each representing one share of common stock, bringing his direct common stock holdings to 4,685 shares.
Lang also received options to purchase 6,040 shares of common stock at an exercise price of $65.87 per share, expiring on May 5, 2036. Both the RSUs and options vest in full on the earlier of May 5, 2027 or the next annual stockholder meeting, with RSU settlement deferred until completion of his board service.
Henderson Jeffrey William reported acquisition or exercise transactions in this Form 4 filing.
HALOZYME THERAPEUTICS director Jeffrey William Henderson received equity compensation in the form of stock and options. He was granted 3,796 restricted stock units, each representing one share of common stock, and an option to purchase 6,040 shares at $65.87 per share.
The RSU and stock option grants are part of the company’s director compensation program. Both awards vest in full on the earlier of May 5, 2027 or the date of the company’s next annual meeting of stockholders. Following the grants, he directly holds 36,572 shares of common stock.
HALOZYME THERAPEUTICS, INC. director Barbara Gayle Duncan received equity compensation in the form of restricted stock units and stock options. She was granted 3,796 shares of common stock as annual RSUs and an option for 6,040 shares of common stock.
The RSUs and options are part of the issuer's director compensation program and each RSU represents one share of common stock. Both awards vest in full on the earlier of May 5, 2027 or the date of the next annual meeting of stockholders. Following the RSU grant, she holds 23,715 common shares directly, and the new option has an exercise price of $65.87 per share and expires on May 5, 2036.
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton received equity compensation awards on May 5, 2026. She was granted 6,796 restricted stock units (RSUs), each representing one share of common stock, and a stock option for 6,040 shares at an exercise price of $65.87 per share.
Both the RSU grant and the option grant will vest in full on the earlier of May 5, 2027 or the date of the company’s next annual meeting of stockholders. Following the RSU award, Connaughton directly holds 45,294 shares of common stock.
Halozyme Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on May 5, 2026. Of 118,474,300 common shares outstanding as of the record date, 104,138,244 shares were represented, meaning a large majority of shareholders participated.
Stockholders elected Bernadette Connaughton and Matthew L. Posard as Class I directors for three-year terms, with each receiving more than a majority of the outstanding shares. They also approved, on an advisory basis, the compensation of the company’s named executive officers and ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton sold 1,625 shares of common stock in an open-market transaction at $63.48 per share. After this sale, she directly holds 38,498 shares. The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance.
Halozyme Therapeutics Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 6,173,547 shares of Common Stock, representing 5.21% of the class as reported for the period ending 03/31/2026. The filing shows sole dispositive power of 6,173,547 shares and sole voting power of 902,329 shares. The filing is signed by Ashley Grim on 04/30/2026.
Halozyme Therapeutics Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 6,173,547 shares of Common Stock, representing 5.21% of the class as reported for the period ending 03/31/2026. The filing shows sole dispositive power of 6,173,547 shares and sole voting power of 902,329 shares. The filing is signed by Ashley Grim on 04/30/2026.